Drug Profile
Research programme: chromatin modifying protein inhibitors - Epizyme
Latest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Epizyme
- Class Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer